Skip to main content

Advertisement

SpringerLink
Log in

Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

The effect of anti-epidermal growth factor receptor (EGFR) antibody-containing chemotherapy on appendiceal signet-ring cell carcinoma (SRCC) remains unknown. Herein, we report three patients, diagnosed as having synchronous metastases, who underwent this treatment for unresectable appendiceal SRCC with RAS wild type. Cases 1, 2, and 3 received FOLFOX with panitumumab, FOLFOX with cetuximab, and FOLFIRI with cetuximab, respectively, and their progression-free survival were 6.2, 7.2, and 18.7 months, respectively. The subsequent anti-vascular endothelial growth factor antibody-containing therapy was ineffective, and their overall survival was 8.2, 11.4, and 22.9 months, respectively. The anti-EGFR antibody-containing chemotherapy showed moderate efficacy for appendiceal SRCC. Further studies including molecular analysis should be needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. McCusker ME, Coté TR, Clegg LX et al (2002) Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer 94:3307–3312

    Article  Google Scholar 

  2. Connor SJ, Hanna GB, Frizelle FA (1998) Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 41:75–80

    Article  CAS  Google Scholar 

  3. Kaji S, Harada N, Suzuki S et al (2009) A clinicopathological study of four cases of primary appendiceal cancer (in Japanese). J Jpn Coll Surg 34:17–21

    Google Scholar 

  4. Ozawa H, Kotake K, Matsui K et al (2012) Statistics of appendiceal malignant tumors: data from the JSCCR Registry and the Japan Autopsy Annual Database (in Japanese). Daichougan Front 5:150–153

    Google Scholar 

  5. Henry M, Delavari N, Webber J (2020) Undiagnosed case of signet ring cell colorectal carcinoma: a case report and review of the literature. Clin Colorectal Cancer 19:e83–e86

    Article  Google Scholar 

  6. Nitecki SS, Wolff BG, Schlinkert R et al (1994) The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 219:51–57

    Article  CAS  Google Scholar 

  7. Tung SY, Wu CS, Chen PC (1996) Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study. Am J Gastroenterol 91:2195–2199

    CAS  PubMed  Google Scholar 

  8. Sim HL, Tan KY, Poon PL et al (2008) Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries. World J Gastroenterol 14:2118–2120

    Article  Google Scholar 

  9. McGory ML, Maggard MA, Kang H et al (2005) Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 48:2264–2271

    Article  Google Scholar 

  10. Turaga KK, Pappas SG, Gamblin T (2012) Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 19:1379–1385

    Article  Google Scholar 

  11. Lieu CH, Lambert LA, Wolff RA et al (2012) Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol 23:652–658

    Article  CAS  Google Scholar 

  12. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019

    Article  CAS  Google Scholar 

  13. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  Google Scholar 

  14. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

    Article  CAS  Google Scholar 

  15. Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034

    Article  CAS  Google Scholar 

  16. Dahabreh IJ, Terasawa T, Castaldi PJ et al (2011) Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 154:37–49

    Article  Google Scholar 

  17. Ang CS, Shen JP, Hardy-Abeloos CJ et al (2018) Genomic landscape of appendiceal neoplasms. JCO Precis Oncol 2:1–18

    Google Scholar 

  18. Raghav KP, Shetty AV, Kazmi SM et al (2013) Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18:1270–1277

    Article  CAS  Google Scholar 

  19. Choe JH, Overman MJ, Fournier KF et al (2015) Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol 22:2578–2584

    Article  CAS  Google Scholar 

  20. Yoshizawa J, Shirozaki T, Inoue K et al (2013) A case of advanced signet ring cell carcinoma of the appendix that responded to S-1 and docetaxel (in Japanese). Nihon Shokakibyo Gakkai Zasshi 110:1934–1942

    PubMed  Google Scholar 

  21. Powell ED, Macdonald DB, Elkeilani AM et al (2009) A case of appendiceal adenocarcinoma with clinical benefit from FOLFOX and bevacizumab. Case Rep Oncol 2:111–115

    Article  Google Scholar 

  22. Ko YH, Jung CK, Oh SN et al (2008) Primary signet ring cell carcinoma of the appendix: a rare case report and our 18-year experience. World J Gastroenterol 14:5763–5768

    Article  Google Scholar 

  23. Kulkarni RV, Ingle SB, Siddiqui S (2015) Primary signet ring cell carcinoma of the appendix: a rare case report. World J Clin Cases 3:538–541

    Article  Google Scholar 

  24. Harada S, Tsuchida K, Shibuya T et al (2015) Experience of the pharmacotherapy against appendix and sigmoid colon signet ring cell carcinoma with the peritoneal dissemination (in Japanese). Gan To Kagaku Ryoho 42:1268–1270

    PubMed  Google Scholar 

  25. Kusakari C, Soda H, Nakamura Y et al (2007) Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil. Lung Cancer 56:139–141

    Article  Google Scholar 

  26. Tejpar S, Stintzing S, Ciardiello F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 3:194–201

    Article  Google Scholar 

  27. Shen H, Yang J, Huang Q et al (2015) Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol 21:6470–6478

    Article  CAS  Google Scholar 

  28. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237

    Article  CAS  Google Scholar 

  29. Borazanci E, Millis SZ, Kimbrough J et al (2017) Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. J Gastrointest Oncol 8:164–172

    Article  Google Scholar 

  30. Shirota Y, Stoehlmacher J, Brabender J et al (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304

    Article  CAS  Google Scholar 

  31. Kim SH, Kwon HC, Oh SY et al (2009) Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32:38–43

    Article  CAS  Google Scholar 

  32. Shaojun C, Li H, Haixin H et al (2018) Expression of topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther 19:153–159

    Article  Google Scholar 

  33. Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506

    Article  Google Scholar 

  34. Cremolini C, Antoniotti C, Stein A et al (2020) Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol 38(28):3314–3324. https://doi.org/10.1200/JCO.20.01225

    Article  CAS  Google Scholar 

  35. Glockzin G, Zeman F, Croner RS et al (2018) Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 COMBATAC trial. Clin Colorectal Cancer 17:285–296

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (http://www.editage.com) for English editing.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Suguru Hirose, Chiaki Enami, Yoshimi Ito, Tsubasa Onoda, Yutaro Sugiyama, Hirosumi Suzuki, Miho Nagafuchi, Takafumi Ikeda, Yusuke Niisato, Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki & Hideo Suzuki

  2. Department of Pathology, University of Tsukuba Hospital, Ibaraki, Japan

    Natsumi Kawamatsu

Authors
  1. Suguru Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiaki Enami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natsumi Kawamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshimi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tsubasa Onoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yutaro Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirosumi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miho Nagafuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takafumi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yusuke Niisato
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takeshi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshiyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Toshikazu Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hideo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshikazu Moriwaki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirose, S., Enami, C., Kawamatsu, N. et al. Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases. Int Canc Conf J 11, 17–22 (2022). https://doi.org/10.1007/s13691-021-00507-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-021-00507-w

Keywords

Search

Navigation